Grufity logoGrufity logo

West Pharmaceutical Services Inc Stock Research

WST

334.30USD+2.45(+0.74%)Delayed

Market Summary

USD334.30+2.45
Delayed
0.74%

WST Alerts

WST Stock Price

WST RSI Chart

WST Valuation

Market Cap

24.8B

Price/Earnings (Trailing)

42.28

Price/Sales (Trailing)

8.58

EV/EBITDA

29.93

Price/Free Cashflow

56.38

WST Price/Sales (Trailing)

WST Profitability

EBT Margin

23.55%

Return on Equity

21.82%

Return on Assets

16.2%

Free Cashflow Yield

1.77%

WST Fundamentals

WST Revenue

Revenue (TTM)

2.9B

Revenue Y/Y

-3.02%

Revenue Q/Q

3.17%

WST Earnings

Earnings (TTM)

585.9M

Earnings Y/Y

-30.26%

Earnings Q/Q

-14.59%

Price Action

52 Week Range

206.19424.00
(Low)(High)

Last 7 days

-0.6%

Last 30 days

9.4%

Last 90 days

42.2%

Trailing 12 Months

-18.1%

WST Financial Health

Current Ratio

3.7

Debt/Equity

0.08

Debt/Cashflow

3.46

WST Investor Care

Dividend Yield

0.22%

Dividend/Share (TTM)

0.74

Buy Backs (1Y)

0.13%

Diluted EPS (TTM)

7.73

Peers (Alternatives to West Pharmaceutical Services)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.7B
31.5B
-0.78% -13.30%
25.07
5.74
6.85% 12.06%
171.9B
43.7B
-4.52% -15.68%
24.79
3.94
1.34% -1.95%
105.6B
30.8B
-6.73% -24.80%
25.98
3.43
-3.19% -17.38%
40.2B
3.4B
1.94% -10.16%
59.26
11.95
4.73% -8.83%
24.8B
2.9B
9.41% -18.15%
42.28
8.58
1.95% -11.47%
MID-CAP
10.5B
847.1M
5.10% 33.54%
-5.2K
12.36
13.32% -137.89%
5.6B
935.1M
39.79% 59.89%
199.63
5.99
119.91% 139.38%
3.9B
630.7M
-5.79% -41.33%
-242.52
6.24
25.40% -128.45%
3.7B
-
-3.05% -21.16%
3.27
1.42
- -
SMALL-CAP
1.5B
301.6M
2.29% 56.91%
-550.1
4.93
-3.75% -104.51%
1.1B
237.3M
15.32% -32.47%
-24.23
4.63
6.59% 84.02%
958.4M
257.3M
13.67% -32.65%
-48.19
3.72
1.41% -1632.49%
51.1M
7.9M
-14.38% -62.64%
-1.65
6.49
23.02% -7.81%
766.7K
37.4M
-50.00% -99.61%
-0.01
0.02
-2.49% 10.49%

Financials for West Pharmaceutical Services

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue-0.8%2,8872,9092,9292,8812,832
Gross Profit-3.3%1,1361,1751,1951,1891,176
  S&GA Expenses-3.7%317329355366363
  R&D Expenses3.9%59.0056.0056.0055.0053.00
EBITDA-6.5%805861906893-
EBITDA Margin-5.8%0.28*0.30*0.31*0.31*-
Earnings Before Taxes-7.3%680733778762749
EBT Margin-6.5%0.24*0.25*0.27*0.26*-
Interest Expenses-10.2%8.009.008.009.008.00
Net Income-7.1%586631686684662
Net Income Margin-6.4%0.20*0.22*0.23*0.24*-
Free Cahsflow13.3%439388402382-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets9.0%3,6173,3173,3623,2953,314
  Current Assets10.7%1,9201,7341,7711,6911,742
    Cash Equivalents22.7%894729719668763
  Inventory0.4%415413412417378
  Net PPE8.4%1,1581,0691,0771,0661,058
  Goodwill3.2%107104107109110
Liabilities10.2%932846937969978
  Current Liabilities13.6%519457565585594
  Long Term Debt-16.9%209252253253-
    LT Debt, Current-95.0%2.0044.0044.0044.00-
    LT Debt, Non Current-0.2%207207208208209
Shareholder's Equity8.7%2,6852,4712,4242,3262,335
  Retained Earnings2.6%2,9882,9132,7932,6172,457
  Additional Paid-In Capital0.7%232231225220249
Accumulated Depreciation5.5%1,2281,1641,1691,1711,158
Shares Outstanding0.1%74.0074.0074.0074.0074.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations10.7%724654675647584
  Share Based Compensation-12.2%24.0027.0032.0037.0038.00
Cashflow From Investing-6.4%-288-270-277-266-253
Cashflow From Financing-1.1%-293-290-220-184-168
  Dividend Payments1.5%54.0053.0052.0052.0051.00
  Buy Backs0.0%203203176147137

Risks for WST

What is the probability of a big loss on WST?

58.1%


Probability that West Pharmaceutical Services stock will be more than 20% underwater in next one year

18.5%


Probability that West Pharmaceutical Services stock will be more than 30% underwater in next one year.

10.8%


Probability that West Pharmaceutical Services stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does WST drawdown profile look like?

Y-axis is the maximum loss one would have experienced if West Pharmaceutical Services was unfortunately bought at previous high price.

Drawdowns

Returns for WST

Cumulative Returns on WST

27.1%


10-Year Cumulative Returns

26.8%


7-Year Cumulative Returns

31.6%


5-Year Cumulative Returns

35.3%


3-Year Cumulative Returns

What are the long-term rolling returns for WST?

FIve years rolling returns for West Pharmaceutical Services.

Annualized Returns

Which funds bought or sold WST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
sold off
-100
-228,000
-
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-82.81
-49,141,200
9,669,820
0.01%
2023-03-10
MATHER GROUP, LLC.
sold off
-100
-249,000
-
-%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
-586
9,414
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-19.43
-241,000
804,000
-%
2023-02-28
Voya Investment Management LLC
added
0.26
-477,294
11,145,700
0.02%
2023-02-24
NATIXIS
added
96.14
1,058,190
2,270,190
0.01%
2023-02-24
National Pension Service
added
10.28
876,551
27,515,900
0.05%
2023-02-24
SRS Capital Advisors, Inc.
new
-
99,082
99,082
0.01%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-73,000
1,597,000
0.02%

1–10 of 49

Latest Funds Activity

Are funds buying WST calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own WST
No. of Funds

West Pharmaceutical Services News

Nasdaq

Merit Medical (MMSI) Down 0.7% Since Last Earnings Report: Can It ....

Nasdaq,
2 days ago

DirectorsTalk Interviews

Schedule 13G FIlings of West Pharmaceutical Services

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
3.1%
2,301,161
SC 13G/A
Feb 09, 2023
vanguard group inc
12.14%
8,988,409
SC 13G/A
Jan 24, 2023
blackrock inc.
11.0%
8,148,624
SC 13G
Feb 14, 2022
price t rowe associates inc /md/
8.4%
6,241,901
SC 13G/A
Feb 04, 2022
franklin resources inc
3.8%
2,848,869
SC 13G/A
Jan 27, 2022
blackrock inc.
10.9%
8,094,288
SC 13G/A
Jan 25, 2022
blackrock inc.
10.9%
8,094,288
SC 13G/A
Apr 12, 2021
blackrock inc.
10.1%
7,467,809
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
6.2%
4,624,247
SC 13G/A
Feb 10, 2021
vanguard group inc
11.21%
8,289,370
SC 13G/A

WST Fair Value

West Pharmaceutical Services fair value in different scenarios

The table shows the Fair Value estimates for West Pharmaceutical Services for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

122.88

-63.24%

150.44

-55.00%

214.70

-35.78%

298.78

-10.63%

403.03

20.56%
Current Inflation

113.04

-66.19%

136.41

-59.20%

190.51

-43.01%

260.94

-21.94%

348.15

4.14%
Very High Inflation

100.93

-69.81%

119.48

-64.26%

162.06

-51.52%

217.19

-35.03%

285.37

-14.64%

Historical West Pharmaceutical Services Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of West Pharmaceutical Services

View All Filings
Date Filed Form Type Document
Mar 22, 2023
4
Insider Trading
Mar 22, 2023
4
Insider Trading
Mar 15, 2023
ARS
ARS
Mar 15, 2023
DEF 14A
DEF 14A
Mar 15, 2023
DEFA14A
DEFA14A
Mar 09, 2023
4
Insider Trading
Feb 23, 2023
4
Insider Trading
Feb 23, 2023
4
Insider Trading
Feb 23, 2023
4
Insider Trading
Feb 23, 2023
4
Insider Trading

Latest Insider Trading transactions for WST

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-09
Abraham Silji
sold
-483,850
322
-1,500
svp, chief technology officer
2023-03-07
Green Eric Mark
sold
-14,183,500
322
-44,000
president & ceo
2023-03-07
Green Eric Mark
acquired
2,869,000
57.38
50,000
president & ceo
2023-03-01
Birkett Bernard
sold
-13,686
318
-43.00
sr vp, cfo & coo
2023-03-01
Abraham Silji
acquired
74,477
318
234
svp, chief technology officer
2023-02-21
Lai Quintin J
acquired
347,775
306
1,134
vp corp development & strategy
2023-02-21
Abraham Silji
acquired
697,390
306
2,274
chief digital & trans officer
2023-02-21
Witherspoon Charles
acquired
124,819
306
407
vp & treasurer
2023-02-21
Green Eric Mark
acquired
4,533,650
306
14,783
president & ceo
2023-02-21
Birkett Bernard
acquired
1,108,340
306
3,614
sr vp, cfo & coo

1–10 of 50

Eric M. Green
10100
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

WST Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Net sales$ 2,886.9$ 2,831.6$ 2,146.9
Cost of goods and services sold1,750.71,655.81,379.1
Gross profit1,136.21,175.8767.8
Research and development58.552.846.9
Selling, general and administrative expenses316.9362.8302.0
Other expense (income) (Note 16)26.87.912.0
Operating profit734.0752.3406.9
Interest expense7.98.28.2
Interest income(5.1)(1.0)(1.4)
Other nonoperating expense (income)51.3(3.8)(1.2)
Income before income taxes and equity in net income of affiliated companies679.9748.9401.3
Income tax expense114.7107.272.5
Equity in net income of affiliated companies(20.7)(20.1)(17.4)
Net income$ 585.9$ 661.8$ 346.2
Net income per share:   
Basic (in dollars per share)$ 7.87$ 8.89$ 4.68
Diluted (in dollars per share)$ 7.73$ 8.67$ 4.57
Weighted average shares outstanding:   
Basic (in shares)74.474.473.9
Diluted (in shares)75.876.375.8

WST Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 894.3$ 762.6
Accounts receivable, net507.4489.0
Inventories414.8378.4
Other current assets103.0112.0
Total current assets1,919.51,742.0
Property, plant and equipment2,386.62,215.0
Less: accumulated depreciation and amortization1,228.31,157.5
Property, plant and equipment, net1,158.31,057.5
Operating lease right-of-use assets104.469.3
Investments in affiliated companies204.9207.7
Goodwill107.3109.9
Intangible assets, net18.423.0
Deferred income taxes65.648.5
Pension and other postretirement benefits0.316.7
Other noncurrent assets38.139.2
Total Assets3,616.83,313.8
Current liabilities:  
Notes payable and other current debt2.244.2
Accounts payable215.4232.2
Pension and other postretirement benefits2.12.4
Accrued salaries, wages and benefits76.8116.3
Income taxes payable24.826.3
Operating lease liabilities16.09.3
Other current liabilities181.7163.4
Total current liabilities519.0594.1
Long-term debt206.7208.8
Deferred income taxes14.34.9
Pension and other postretirement benefits28.240.5
Operating lease liabilities93.063.0
Deferred compensation benefits19.128.9
Other long-term liabilities51.638.2
Total Liabilities931.9978.4
Commitments and contingencies (Note 18)
Equity:  
Preferred stock, 3.0 million shares authorized; 0.0 shares issued and outstanding in 2022 and 20210.00.0
Common stock, par value $0.25 per share; 200 million shares authorized; shares issued: 75.3 million in 2022 and 2021; shares outstanding: 74.1 million and 74.2 million in 2022 and 202118.818.8
Capital in excess of par value232.2249.0
Retained earnings2,987.82,456.7
Accumulated other comprehensive loss(183.0)(159.6)
Treasury stock, at cost (1.2 million and 1.1 million shares in 2022 and 2021)(370.9)(229.5)
Total Equity2,684.92,335.4
Total Liabilities and Equity$ 3,616.8$ 3,313.8